Gender-specific association of coronary artery calcium and lipoprotein parameters: The Heinz Nixdorf Recall Study

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 531-540

  Erbel, Raimund ^a   Lehmann, Nils ^b   Churzidse, Sofia ^a   Möhlenkamp, Stefan ^c   Moebus, Susanne ^b   Mahabadi, Amir A ^a   Schmermund, Axel ^d   Stang, Andreas ^e   Dragano, Nico ^f   Grönemeyer, Dietrich ^g   Seibel, Rainer ^h   Kälsch, Hagen ^a   Bauer, Marcus ^a   Bröcker Preuss, Martina ⁱ   Mann, Klaus ⁱ   Jöckel, Karl Heinz ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c Medical Clinic II   (Germany)

^d Cardioangiological Center Bethanien   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f Department of Orthopedic Surgery   (Germany)

^g UNIVERSITY OF WITTEN HERDECKE   (Germany)

^h Diagnosticum Mülheim   (Germany)

ⁱ Division of Clinical Chemistry and Laboratory Medicine   (Germany)

Author keywords

ApoB ApoA 1; Atherosclerosis; Coronary artery calcification; Lipoprotein (a); Non high density lipoprotein cholesterol

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIABETES MELLITUS; ELECTRON BEAM TOMOGRAPHY; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL;

APOB/APOA-1; ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; LIPOPROTEIN (A); NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEIN(A); MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR CALCIFICATION;

EID: 84880643328     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.015     Document Type: Article

References (47)

1. Agatston A.S., Janowitz W.R., Hildner F.J., Zusmer N.R., Viamonte M., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. JAm Coll Cardiol 1990, 15:827-832.
2. Detrano R., Guerci A.D., Carr J.J., et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. NEngl J Med 2008, 358:1336-1345.
3. Vliegenthart R., Oudkerk M., Hofman A., et al. Coronary calcification improves cardiovascular risk prediction in the elderly. Circulation 2005, 112:572-577.
4. Erbel R., Möhlenkamp S., Moebus S., et al. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis: the Heinz Nixdorf Recall study. JAm Coll Cardiol 2010, 56:1397-1406. Heinz Nixdorf Recall Study Investigative Group.
5. Martin S.S., Qasim A.N., Wolfe M., et al. Comparison of high-density lipoprotein cholesterol to apolipoprotein A-I and A-II to predict coronary calcium and the effect of insulin resistance. Am J Cardiol 2011, 107:393-398.
6. Orakzai S.H., Nasir K., Blaha M., Blumenthal R.S., Raggi P. Non-HDL cholesterol is strongly associated with coronary artery calcification in asymptomatic individuals. Atherosclerosis 2009, 202:289-295.
7. Simprini L.A., Villines T.C., Rich M., Taylor A.J. The relationship between subclinical atherosclerosis, non-high-density lipoprotein cholesterol, exercise, and diet among male participants of the PACC Project. JClin Lipidol 2012, 6:174-179.
8. Qasim A.N., Martin S.S., Mehta N.N., et al. Lipoprotein (a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011, 150:17-21.
9. Sung K.C., Wild S.H., Kwag H.J., Byrne C.D. Fatty liver, insulin resistance, and features of metabolic syndrome: relationship with coronary artery calcium in 10,153 people. Diabetes Care 2012, 35:2359-2364.
10. Prado K.B., Shugg S., Backstrand J.R. Low-density lipoprotein particle number predicts coronary artery calcification in asymptomatic adults at intermediate risk of cardiovascular disease. JClin Lipidol 2011, 5:408-413.
11. Millán J., Pintó X., Muñoz A., et al. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag 2009, 5:757-765.
12. Walldius G., Jungner I., Aastveit A.H., Holme I., Furberg C.D., Sniderman A.D. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clin Chem Lab Med 2004, 42:1355-1363.
13. Sniderman A.D., Jungner I., Holme I., Aastveit A., Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. JIntern Med 2006, 259:455-461.
14. Walldius G., Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. JIntern Med 2006, 259:493-519.
15. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. JIntern Med 2006, 259:247-258.
16. Scanu A.M., Nakajima K., Edelstein C. Apolipoprotein (a): structure and biology. Front Biosci 2001, 6:D546-D554.
17. Spence J.D., Koschinsk M. Mechanism of lipoprotein (a) pathogenicity: prothrombozic, proatherosclerotic, or both?. ATVB 2012, 32:1550-1551.
18. Di Angelantonio E., Gao P., Pennells L., et al. Lipid-related markers and cardiovascular disease prediction. JAm Med Assoc 2012, 307:2499-2506. Emerging Risk Factors Collaboration.
19. Schmermund A., Möhlenkamp S., Stang A., et al. Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: rationale and design of the Heinz Nixdorf RECALL Study. Risk factors, evaluation of coronary calcium and lifestyle. Am Heart J 2002, 144:212-218.
20. Stang A., Moebus S., Dragano N., et al. Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. Eur J Epidemiol 2005, 20:489-496. Heinz Nixdorf Recall Study Investigation Group.
21. Dragano N., Verde P.E., Moebus S., et al. Subclinical coronary atherosclerosis is more pronounced in men and women with lower socio-economic status: associations in a population-based study. Coronary atherosclerosis and social status. Eur J Cardiovasc Prev Rehabil 2007, 14:568-574. Heinz Nixdorf Recall Study.
22. Stang A., Moebus S., Möhlenkamp S., et al. Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. Am J Epidemiol 2006, 164:85-94. Heinz Nixdorf Recall Study Investigative Group.
23. Erbel R., Lehmann N., Möhlenkamp S., et al. Subclinical coronary atherosclerosis predicts cardiovascular risk in different stages of hypertension: result of the Heinz Nixdorf Recall Study. Hypertension 2012, 59:44-53. Heinz Nixdorf Recall Study Investigators.
24. Moebus S., Stang A., Möhlenkamp S., et al. Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort-results of the Heinz Nixdorf Recall Study. Diabetologia 2009, 52:81-89. Heinz Nixdorf Recall Study Group.
25. Michos E.D., Santos R.D., Narla V., et al. Favorable cardiovascular risk factor profile is associated with reduced prevalence of coronary artery calcification and inflammation in asymptomatic nondiabetic white men. Prev Cardiol 2008, 11:189-194.
26. Hoffmann B., Moebus S., Möhlenkamp S., et al. Residential exposure to traffic is associated with coronary atherosclerosis. Circulation 2007, 116:489-496. Heinz Nixdorf Recall Study Investigative Group.
27. Bielak L.F., Yu P., Ryan K.A., et al. Differences in prevalence and severity of coronary artery calcification between two non-hispanic white populations with diverse lifestyles. Atherosclerosis 2008, 196:888-895.
28. Hecht H.S., Superko H.R., Smith L.K., McColgan B.P. Relation of coronary artery calcium identified by electron beam tomography to serum lipoprotein levels and implications for treatment. Am J Cardiol 2001, 87:406-412.
29. Allison M.A., Wright C.M. Acomparison of HDL and LDL cholesterol for prevalent coronary calcification. Int J Cardiol 2004, 95:55-60.
30. Paramsothy P., Katz R., Owens D.S., Burke G.L., Probstfield J.L., O'Brien K.D. Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol 2010, 105:352-358.
31. Hartiala O., Magnussen C.G., Kajander S., et al. Adolescence risk factors are predictive of coronary artery calcification at middle age: the cardiovascular risk in young Finns study. JAm Coll Cardiol 2012, 60:1364-1370.
32. Jöckel K.H., Lehmann N., Jaeger B.R., et al. Smoking cessation and subclinical atherosclerosis-results from the Heinz Nixdorf Recall Study. Atherosclerosis 2009, 203:221-227.
33. Shaw L.J., Raggi P., Berman D.S., Callister T.Q. Coronary artery calcium as a measure of biologic age. Atherosclerosis 2006, 188:112-119.
34. Grundy S.M., Cleeman J.I., Daniels S.R., American Heart Association, National Heart, Lung, and Blood Institute, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
35. Perk J., De Backer G., Gohlke H., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012, 33:1635-1701.
36. Cooney M.T., Dudina A., De Bacquer D., et al. How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators. Eur J Cardiovasc Prev Rehabil 2009, 16:304-314. SCORE Investigators.
37. Cooney M.T., Dudina A., De Bacquer D., et al. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk. Atherosclerosis 2009, 206:611-616. SCORE investigators.
38. Barter P.J., Caulfield M., Eriksson M., et al. Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 2007, 357:2109-2122.
39. Di Angelantonio E., Sarwar N., Perry P., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAm Med Assoc 2009, 302:1993-2000. Emerging Risk Factors Collaboration.
40. Ridker P.M. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?. Clin Chem 2008, 54:11-13.
41. Sarwar N., Sandhu M.S., Ricketts S.L., et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
42. Simon A., Chironi G., Gariepy J., Del Pino M., Levenson J. Differences between markers of atherogenic lipoproteins in predicting high cardiovascular risk and subclinical atherosclerosis in asymptomatic men. Atherosclerosis 2005, 179:339-344.
43. Greif M., Arnoldt T., von Ziegler F., et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur J Intern Med 2013, 24:75-79.
44. Scanu A.M. The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr Cardiol Rep 2001, 3:385-390.
45. Goldhaber S.Z. European Atherosclerosis Society screening recommendations for lipoprotein(a) and high-sensitivity C-reactive protein: double standard or failure of evidence-based medicine?. Clin Chem 2010, 56:1544-1546.
46. Cho I., Chang H.J., Sung J.M., et al. Coronary computed tomographic angiography and risk of all-cause mortality and nonfatal myocardial infarction in subjects without chest pain syndrome from the CONFIRM Registry (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry). Circulation 2012, 126:304-313. CONFIRM Investigators.
47. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment panel III). JAm Med Assoc 2001, 285:2486-2497.